Next Article in Journal
Canadian Consensus Recommendations on the Management of Venous Thromboembolism in Patients with Cancer. Part 1: Prophylaxis
Previous Article in Journal
Establishing a Clinic-Based Pancreatic Cancer and Periampullary Tumour Research Registry in Quebec
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on as a courtesy and upon agreement with Multimed Inc..
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:

Management of egfr tki—Induced Dermatologic Adverse Events

BC Cancer Agency, Vancouver, BC, Canada
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
R.S. McLaughlin Durham Regional Cancer Centre, Lakeridge Health, Oshawa, and Department of Oncology, Queen’s University, Kingston, ON, Canada
Cross Cancer Institute, Edmonton, AB, Canada
The Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
Probity Medical Research, Waterloo, ON, Canada
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(2), 123-132;
Received: 3 January 2015 / Revised: 6 February 2015 / Accepted: 8 March 2015 / Published: 1 April 2015


Targeting the epidermal growth factor receptor (EGFR) pathway has become standard practice for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy, EGFR tyrosine kinase inhibitors (TKIS) have been associated with improved efficacy in patients with an EGFR mutation. Together with the increase in efficacy comes an adverse event (AE) profile different from that of chemotherapy. That profile includes three of the most commonly occurring dermatologic AES: acneiform rash, stomatitis, and paronychia. Currently, no randomized clinical trials have evaluated the treatments for the dermatologic AES that patients experience when taking EGFR TKIS. Based on the expert opinion of the authors, some basic strategies have been developed to manage those key dermatologic AES. Those strategies have the potential to improve patient quality of life and compliance and to prevent inappropriate dose reductions.
Keywords: non-small-cell lung cancer; adverse events; acneiform rash; paronychia; stomatitis; egfr tkis non-small-cell lung cancer; adverse events; acneiform rash; paronychia; stomatitis; egfr tkis

Share and Cite

MDPI and ACS Style

Melosky, B.; Leighl, N.B.; Rothenstein, J.; Sangha, R.; Stewart, D.; Papp, K. Management of egfr tki—Induced Dermatologic Adverse Events. Curr. Oncol. 2015, 22, 123-132.

AMA Style

Melosky B, Leighl NB, Rothenstein J, Sangha R, Stewart D, Papp K. Management of egfr tki—Induced Dermatologic Adverse Events. Current Oncology. 2015; 22(2):123-132.

Chicago/Turabian Style

Melosky, B., N.B. Leighl, J. Rothenstein, R. Sangha, D. Stewart, and K. Papp. 2015. "Management of egfr tki—Induced Dermatologic Adverse Events" Current Oncology 22, no. 2: 123-132.

Article Metrics

Back to TopTop